Literature DB >> 16044149

Activation of the protein kinase B pathway by the HPV-16 E7 oncoprotein occurs through a mechanism involving interaction with PP2A.

David Pim1, Paola Massimi, Stephen M Dilworth, Lawrence Banks.   

Abstract

Protein kinase B (PKB) or Akt is one of several second messenger kinases that are activated by cell attachment and growth factor signaling, and that transmit signals to the cell nucleus to inhibit apoptosis and thereby increase cell survival during proliferation. Other viral proteins target this pathway by increasing PKB/Akt phosphorylation, and this pathway has been implicated in the transformation of human keratinocytes by HPV E6 and E7, together with activated notch 1. Here, we examine how HPV E7 expression affects the phosphorylation of PKB. We show that HPV-16 E7 increases the level of phosphorylation of PKB in response to serum stimulation, by a mechanism independent of downregulation of PTEN phosphatase, a known inhibitor of the PI3K (PI3 kinase) pathway. The use of specific antibodies shows that some proportion of PKB/Akt that is phosphorylated both on threonine 308 and serine 473 is maintained in the presence of E7 in a PI3 kinase-independent manner, and is activated for phosphorylation of BAD, a known downstream target of PKB/Akt. Use of E7 mutants has ruled out both an inhibition of IGFBP-3, a known E7 target and PKB/Akt modulator, and the interaction of E7 with cellular pocket proteins, as being the mechanism for the PKB/Akt stimulation. PKB binds PP2A and is a known substrate of PP2A. Here, we show that HPV E7 also binds to both the 35 kDa catalytic and 65 kDa structural subunits of PP2A, an interaction that sequesters these subunits and inhibits their interaction with PKB, thereby maintaining PKB/Akt signaling by inhibiting its dephosphorylation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044149     DOI: 10.1038/sj.onc.1208935

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  75 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

Review 2.  Show me your license, please: deregulation of centriole duplication mechanisms that promote amplification.

Authors:  Christopher W Brownlee; Gregory C Rogers
Journal:  Cell Mol Life Sci       Date:  2012-08-15       Impact factor: 9.261

3.  HPV-16 E2 contributes to induction of HPV-16 late gene expression by inhibiting early polyadenylation.

Authors:  Cecilia Johansson; Monika Somberg; Xiaoze Li; Ellenor Backström Winquist; Joanna Fay; Fergus Ryan; David Pim; Lawrence Banks; Stefan Schwartz
Journal:  EMBO J       Date:  2012-05-22       Impact factor: 11.598

4.  Physiological regulation of Akt activity and stability.

Authors:  Yong Liao; Mien-Chie Hung
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

5.  E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1.

Authors:  Rosita Accardi; Rosa Rubino; Mariafrancesca Scalise; Tarik Gheit; Naveed Shahzad; Miranda Thomas; Lawrence Banks; Cesare Indiveri; Bakary S Sylla; Rosa A Cardone; Stephan J Reshkin; Massimo Tommasino
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

6.  Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy.

Authors:  Zurab Surviladze; Rosa T Sterk; Sergio A DeHaro; Michelle A Ozbun
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

7.  PP2A-dependent disruption of centrosome replication and cytoskeleton organization in Drosophila by SV40 small tumor antigen.

Authors:  S Kotadia; L R Kao; S A Comerford; R T Jones; R E Hammer; T L Megraw
Journal:  Oncogene       Date:  2008-07-28       Impact factor: 9.867

8.  Phosphorylation of the human papillomavirus type 16 E1--E4 protein at T57 by ERK triggers a structural change that enhances keratin binding and protein stability.

Authors:  Qian Wang; Alan Kennedy; Papia Das; Pauline B McIntosh; Steven A Howell; Erin R Isaacson; Steven A Hinz; Clare Davy; John Doorbar
Journal:  J Virol       Date:  2009-02-11       Impact factor: 5.103

Review 9.  Glycogen synthase kinase 3 beta: can it be a target for oral cancer.

Authors:  Rajakishore Mishra
Journal:  Mol Cancer       Date:  2010-06-11       Impact factor: 27.401

10.  The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas.

Authors:  Ryan T Anderson; Stephen B Keysar; Daniel W Bowles; Magdalena J Glogowska; David P Astling; J Jason Morton; Phuong Le; Adrian Umpierrez; Justin Eagles-Soukup; Gregory N Gan; Brian W Vogler; Daniel Sehrt; Sarah M Takimoto; Dara L Aisner; Francois Wilhelm; Barbara A Frederick; Marileila Varella-Garcia; Aik-Choon Tan; Antonio Jimeno
Journal:  Mol Cancer Ther       Date:  2013-07-19       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.